Phaseline

Companies › TILT Biotherapeutics

TILT Biotherapeutics: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TILT-123
Oncolytic adenovirus encoding TNFα and IL-2
–Phase 1Lung Cancer; Metastatic Melanoma; Melanoma; Platinum-refractory Ovarian CarcinomaNov 2026
Avelumab
Programmed cell death 1 ligand 1 other
CD274Phase 1MelanomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06125197TILT-123Phase 1Lung CancerOncologyJan 2026
NCT06961786TILT-123Phase 1Metastatic MelanomaOncologyNov 2026
NCT05222932TILT-123Phase 1MelanomaOncologyDec 2026
NCT05222932AvelumabPhase 1MelanomaOncologyDec 2026
NCT05271318TILT-123Phase 1Platinum-refractory Ovarian CarcinomaOncologyMar 2027

Targets

CD274 (1)

Companies with the same targets

AstraZeneca Pfizer IO Biotech ImmuneOncia Therapeutics Akeso Roche Biotheus Suzhou Suncadia Biopharmaceuticals Shine-On Biomedical 3D Medicines (Sichuan)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.